“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.
In this interview, Mark A. Moyad, MD, MPH discusses the 2011 Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the recently completed VITamin D and OmegA-3 TriaL (VITAL), both of which explored the impact of vitamin D on urologic endpoints. Moyad is the Jenkins/Pomkempner Director of Complementary Alternative Medicine in the Department of Urology at the University of Michigan Medical Center.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.